243 related articles for article (PubMed ID: 14984943)
1. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma.
Arts HJ; de Jong S; Hollema H; ten Hoor K; van der Zee AG; de Vries EG
Gynecol Oncol; 2004 Mar; 92(3):794-800. PubMed ID: 14984943
[TBL] [Abstract][Full Text] [Related]
2. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
3. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.
Spierings DC; de Vries EG; Timens W; Groen HJ; Boezen HM; de Jong S
Clin Cancer Res; 2003 Aug; 9(9):3397-405. PubMed ID: 12960128
[TBL] [Abstract][Full Text] [Related]
4. [Expression of different receptors of the apoptosis inducing gene TRAIL in human ovarian tumors].
Li XG; Zhang Y; Chen BL
Hunan Yi Ke Da Xue Xue Bao; 2000 Oct; 25(5):471-3. PubMed ID: 12212122
[TBL] [Abstract][Full Text] [Related]
5. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation.
van Noesel MM; van Bezouw S; Salomons GS; Voûte PA; Pieters R; Baylin SB; Herman JG; Versteeg R
Cancer Res; 2002 Apr; 62(7):2157-61. PubMed ID: 11929838
[TBL] [Abstract][Full Text] [Related]
6. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.
Mérino D; Lalaoui N; Morizot A; Schneider P; Solary E; Micheau O
Mol Cell Biol; 2006 Oct; 26(19):7046-55. PubMed ID: 16980609
[TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4, DR5, DcR1, and DcR2.
Liu XS; Zhu Y; Han WN; Li YN; Chen LH; Jia W; Song CJ; Liu F; Yang K; Li Q; Jin BQ
Hybrid Hybridomics; 2003 Apr; 22(2):121-5. PubMed ID: 12831538
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.
Jaganathan J; Petit JH; Lazio BE; Singh SK; Chin LS
Neurosurg Focus; 2002 Sep; 13(3):ecp1. PubMed ID: 15844877
[TBL] [Abstract][Full Text] [Related]
9. [The expression of TRAIL, TRAIL-R (DR4, DcR1) and Fas-L in patients with ovarian cancer].
Li CM; Peng ZL; Yang KX
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 May; 36(3):341-3. PubMed ID: 15931863
[TBL] [Abstract][Full Text] [Related]
10. Rel/NF-kappaB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1.
Bernard D; Quatannens B; Vandenbunder B; Abbadie C
J Biol Chem; 2001 Jul; 276(29):27322-8. PubMed ID: 11350953
[TBL] [Abstract][Full Text] [Related]
11. Molecular determinants of response to TRAIL in killing of normal and cancer cells.
Kim K; Fisher MJ; Xu SQ; el-Deiry WS
Clin Cancer Res; 2000 Feb; 6(2):335-46. PubMed ID: 10690508
[TBL] [Abstract][Full Text] [Related]
12. Perturbation of the tumor necrosis factor--related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5.
Horak P; Pils D; Kaider A; Pinter A; Elandt K; Sax C; Zielinski CC; Horvat R; Zeillinger R; Reinthaller A; Krainer M
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8585-91. PubMed ID: 16361541
[TBL] [Abstract][Full Text] [Related]
13. The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer.
Duiker EW; van der Zee AG; de Graeff P; Boersma-van Ek W; Hollema H; de Bock GH; de Jong S; de Vries EG
Gynecol Oncol; 2010 Mar; 116(3):549-55. PubMed ID: 19959214
[TBL] [Abstract][Full Text] [Related]
14. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.
Koyama S; Koike N; Adachi S
J Cancer Res Clin Oncol; 2002 Feb; 128(2):73-9. PubMed ID: 11862476
[TBL] [Abstract][Full Text] [Related]
15. Expression of TRAIL (Apo2L), DR4 (TRAIL receptor 1), DR5 (TRAIL receptor 2) and TRID (TRAIL receptor 3) genes in multidrug resistant human acute myeloid leukemia cell lines that overexpress MDR 1 (HL60/Tax) or MRP (HL60/AR).
Kim CH; Gupta S
Int J Oncol; 2000 Jun; 16(6):1137-9. PubMed ID: 10811986
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells.
Bretz JD; Mezosi E; Giordano TJ; Gauger PG; Thompson NW; Baker JR
Cell Death Differ; 2002 Mar; 9(3):274-86. PubMed ID: 11859410
[TBL] [Abstract][Full Text] [Related]
17. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha.
Sheikh MS; Burns TF; Huang Y; Wu GS; Amundson S; Brooks KS; Fornace AJ; el-Deiry WS
Cancer Res; 1998 Apr; 58(8):1593-8. PubMed ID: 9563466
[TBL] [Abstract][Full Text] [Related]
18. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis.
Meng RD; McDonald ER; Sheikh MS; Fornace AJ; El-Deiry WS
Mol Ther; 2000 Feb; 1(2):130-44. PubMed ID: 10933923
[TBL] [Abstract][Full Text] [Related]
19. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract.
Sheikh MS; Huang Y; Fernandez-Salas EA; El-Deiry WS; Friess H; Amundson S; Yin J; Meltzer SJ; Holbrook NJ; Fornace AJ
Oncogene; 1999 Jul; 18(28):4153-9. PubMed ID: 10435597
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death.
Ibrahim SM; Ringel J; Schmidt C; Ringel B; Müller P; Koczan D; Thiesen HJ; Löhr M
Pancreas; 2001 Jul; 23(1):72-9. PubMed ID: 11451151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
